Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients

Z. Y. G. J. van Lierop*, A. A. Toorop, E. M. E. Coerver, E. A. J. Willemse, E. M. M. Strijbis, N. F. Kalkers, B. Moraal, F. Barkhof, C. E. Teunissen, J. Killestein, Z. L. E. van Kempen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.
Original languageEnglish
JournalMultiple sclerosis journal - experimental, translational and clinical
Volume7
Issue number2
DOIs
Publication statusPublished - 2021

Cite this